Exercise price determined for the exercise of warrants series TO 13 in Alligator Bioscience AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience provides highlights from R&D event 2025
Lund, Sweden – 20 August 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...
Alligator Bioscience to host virtual R&D Day on 19 August 2025
Lund, Sweden – 14 August 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...
Alligator Bioscience announces upcoming presentation of REACtiVe-2 Phase 1 data at ESMO Congress 2025
Lund, Sweden – 25 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Alligator Bioscience comments on Henlius dosing first patient in the US in Phase 3 trial of HLX22 in gastric cancer
Lund, Sweden – 14 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henl ...
Alligator Bioscience AB reports financial results for Q2 2025 and provides a business update
GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 ...
Alligator to present 24-month OPTIMIZE-1 data at ESMO GI 2025
Lund, Sweden, 1 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical- ...
Change in number of shares and votes in Alligator Bioscience AB
During June 2025, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result o ...
Alligator receives positive scientific advice from EMA on Phase 3 trial of mitazalimab
Lund, Sweden, 17 June 2025 — Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-d ...